| Evaluating eligibility criteria of oncology trials using real-world data and AI R Liu, S Rizzo, S Whipple, N Pal, AL Pineda, M Lu, B Arnieri, Y Lu, ... Nature 592 (7855), 629-633, 2021 | 204 | 2021 |
| Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine device N Pal, RR Broaddus, DL Urbauer, N Balakrishnan, A Milbourne, ... Obstetrics & Gynecology 131 (1), 109-116, 2018 | 194 | 2018 |
| Overall survival after pelvic exenteration for gynecologic malignancy SN Westin, V Rallapalli, B Fellman, DL Urbauer, N Pal, MM Frumovitz, ... Gynecologic oncology 134 (3), 546-551, 2014 | 120 | 2014 |
| Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer SN Westin, B Fellman, CC Sun, RR Broaddus, ML Woodall, N Pal, ... American journal of obstetrics and gynecology 224 (2), 191. e1-191. e15, 2021 | 92 | 2021 |
| Effectiveness of PD-(L) 1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD … M Pérol, E Felip, U Dafni, L Polito, N Pal, Z Tsourti, TGN Ton, D Merritt, ... Annals of Oncology 33 (5), 511-521, 2022 | 64 | 2022 |
| PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients SN Westin, Z Ju, RR Broaddus, C Krakstad, J Li, N Pal, KH Lu, ... Molecular oncology 9 (8), 1694-1703, 2015 | 58 | 2015 |
| Systematic pan-cancer analysis of mutation–treatment interactions using large real-world clinicogenomics data R Liu, S Rizzo, S Waliany, MR Garmhausen, N Pal, Z Huang, ... Nature Medicine 28 (8), 1656-1661, 2022 | 34 | 2022 |
| Factors prognostic of survival in advanced-stage uterine serous carcinoma LL Holman, N Pal, DA Iglesias, PT Soliman, N Balakrishnan, A Klopp, ... Gynecologic oncology 146 (1), 27-33, 2017 | 29 | 2017 |
| Machine learning prediction of clinical trial operational efficiency K Wu, E Wu, M DAndrea, N Chitale, M Lim, M Dabrowski, K Kantor, ... The AAPS Journal 24 (3), 57, 2022 | 14 | 2022 |
| Replication of overall survival, progression-free survival, and overall response in chemotherapy arms of non–small cell lung cancer trials using real-world data TGN Ton, N Pal, H Trinh, S Mahrus, MT Bretscher, RJM Machado, ... Clinical Cancer Research 28 (13), 2844-2853, 2022 | 13 | 2022 |
| VP2-2021: Effectiveness of PD-(L) 1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC … S Peters, U Dafni, M Perol, E Felip, L Polito, N Pal, TGN Ton, D Merritt, ... Annals of Oncology 32 (5), 687-688, 2021 | 10 | 2021 |
| Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world … C Julian, N Pal, A Gershon, M Evangelista, H Purkey, P Lambert, Z Shi, ... BMC cancer 23 (1), 352, 2023 | 8 | 2023 |
| Real-world comparative effectiveness of first-line alectinib versus crizotinib in patients with advanced ALK-positive NSCLC with or without baseline central nervous system … Q Zhang, JJ Lin, N Pal, L Polito, H Trinh, M Hilton, V Smoljanović, ... JTO Clinical and Research Reports 4 (4), 100483, 2023 | 7 | 2023 |
| Prospective phase II trial of the Levonorgestrel Intrauterine System (Mirena) to treat complex atypical hyperplasia and grade 1 endometrioid endometrial cancer S Westin, C Sun, R Broaddus, N Pal, V Nath, D Urbauer, K Schmeler, ... Gynecologic Oncology 125, S9, 2012 | 7 | 2012 |
| Phase I trial of sorafenib, bevacizumab, and temsirolimus in advanced solid tumors. SN Westin, ML Smart, N Pal, DL Urbauer, F Janku, JJ Wheler, ... Journal of Clinical Oncology 31 (15_suppl), 2611-2611, 2013 | 4 | 2013 |
| Systematic analysis of off-label and off-guideline cancer therapy usage in a real-world cohort of 165,912 US patients R Liu, L Wang, S Rizzo, MR Garmhausen, N Pal, S Waliany, S McGough, ... Cell Reports Medicine 5 (3), 2024 | 3 | 2024 |
| PTEN loss as a context-dependent determinant of patient outcomes in obese and non-obese endometrioid endometrial cancer patients. Z Ju, SN Westin, R Broaddus, J Li, N Pal, KH Lu, RL Coleman, ... Journal of Clinical Oncology 31 (15_suppl), 5521-5521, 2013 | 3 | 2013 |
| Real-world prevalence of metastasis and overall survival (OS) in patients with advanced non-small cell lung cancer (aNSCLC) with KRAS G12C and with or without STK11 or KEAP1 … C Julian, N Pal, A Gershon, M Evangelista, H Purkey, P Lambert, Z Shi, ... Cancer Res 81, 660, 2021 | 2 | 2021 |
| Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer M Provencio-Pulla, D Pérez-Parente, S Olson, H Hasan, BC Balea, ... Clinical and Translational Oncology 26 (6), 1384-1394, 2024 | 1 | 2024 |
| Applying the Estimand and Target Trial frameworks to external control analyses using observational data: a case study in the solid tumor setting L Polito, Q Liang, N Pal, P Mpofu, A Sawas, O Humblet, K Rufibach, ... Frontiers in Pharmacology 15, 1223858, 2024 | 1 | 2024 |
